Immix Biopharma, Inc.
Close on Oct 19, 2026
- Market cap
- $524.20M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Immix Biopharma has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Immix Biopharma filed with the SEC
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering
Other events · EX-99.1 to Form 8-K
Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
Other events · EX-99.1 to Form 8-K
Biopharma Announces 95% complete response rate in interim update from relapsed/refractory AL Amyloidosis Clinical Trial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Institute for Regenerative Medicine Awards Funding for
Other events · EX-99.1 to Form 8-K
Biopharma Announces Proposed Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
Material agreement · Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated
Material agreement · Other events · EX-99.1 to Form 8-K
Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles
Other events · EX-99.1 to Form 8-K
IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study
Other events · EX-99.1 to Form 8-K
Food and Drug Administration Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening
Other events · EX-99.1 to Form 8-K
Biopharma, Inc. Announces Pricing of Initial Public Offering
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Biopharma, Inc. Announces Closing of Initial Public Offering
Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K